logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Effective Tolvaptan CAS 150683-30-0 EINECS NO 691-537-5

Effective Tolvaptan CAS 150683-30-0 EINECS NO 691-537-5

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 150683-30-0

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:

Tolvaptan CAS 150683-30-0

,

CAS 150683-30-0

CAS NO::
150683-30-0
Appearance::
White To Tan Powder
Molecular Formula::
C26H25ClN2O3
Molecular Weight::
448.94100
EINECS NO::
691-537-5
MDL NO::
MFCD09838782
CAS NO::
150683-30-0
Appearance::
White To Tan Powder
Molecular Formula::
C26H25ClN2O3
Molecular Weight::
448.94100
EINECS NO::
691-537-5
MDL NO::
MFCD09838782
Effective Tolvaptan CAS 150683-30-0 EINECS NO 691-537-5

Product Description:

Product Name: Tolvaptan CAS NO: 150683-30-0


Synonyms:

Tolvaptan;

Samsca;

benzazepine derivative,32;


Chemical & Physical Properties:

Appearance:White to tan powder

Assay :≥99.00%

Density: 1.311±0.06 g/cm3(Predicted)

Melting Point: 219-222℃

Boiling Point: 594.4±50.0℃(Predicted)

Storage Temp.: Refrigerator

Solubility: DMSO: ≥15mg/mL

Pka: 13.00±0.70(Predicted)

Vapour Pressure: 0.0±1.8 mmHg at 25℃

Index of Refraction: 1.664


Safety Information:

WGK Germany: 3


Tolvaptan(trade names Samsca and Jinarc) is an oral selective vasopressin antagonist developed by Otsuka for the treatment of hyponatremia, and it is a non-peptide selective antidiuretic hormone receptor antagonist. The drug can increase the concentration of sodium ions in the plasma, and help the excess water discharge from the urine. The drug could enhance the ability of the kidney to deal with water, and significantly reduce the weight and edema of patients while not accompanied by increased electrolyte excretion, without destroying the blood electrolyte balance. The drug can be used to treat hyponatremia caused by congestive heart failure, various edematous diseases, cirrhosis and antidiuretic hormone deficiency syndrome. The study found that, when the plasma sodium concentration decreased, in order to maintain the balance of sodium concentration inside and outside the cell, extracellular fluid will enter the cell, so the cells will swell. When the brain cells swell, it will lead to a variety of hyponatremia symptoms, including dizziness, weakness, headache, nausea, confusion, consciousness and convulsions. Severe hyponatremia can lead to coma and death. There is no corresponding study of tolvaptan tablets in patients with severe hyponatremia.

It is a selective, competitive arginine vasopressin V2 receptor antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH).


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.